Cargando…

Timely development of vaccines against SARS-CoV-2

Detalles Bibliográficos
Autor principal:	Lu, Shan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144304/ https://www.ncbi.nlm.nih.gov/pubmed/32148172 http://dx.doi.org/10.1080/22221751.2020.1737580

Ejemplares similares

The potential of developing a protective peptide‐based vaccines against SARS‐CoV‐2
por: Shalash, Ahmed O., et al.
Publicado: (2022)

The challenge of emerging SARS-CoV-2 mutants to vaccine development
por: Li, Rong, et al.
Publicado: (2021)

Genomic surveillance of SARS-CoV-2: A race against time
por: Romano, Camila M, et al.
Publicado: (2021)

Vaccine against SARS-CoV-2 in previously infected health care workers
por: Parisi, Saverio Giuseppe
Publicado: (2021)

Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants
por: Su, Shan, et al.
Publicado: (2021)

Evaluation of vaccine effectiveness against SARS‐CoV‐2 variants by serological epitope profiling
por: Li, Cheng, et al.
Publicado: (2023)

Inactivated SARS-CoV-2 vaccine for people with HIV
por: Wolday, Dawit, et al.
Publicado: (2022)

Is there a post-SARS-CoV-2 vaccination dementia?
por: Fiorini, Ana C., et al.
Publicado: (2022)

Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development
por: Cohen, Samuel A., et al.
Publicado: (2020)

Timing vaccination against SARS-CoV-2
por: Barnoud, Coline, et al.
Publicado: (2021)

Unanticipated efficacy of SARS-CoV-2 vaccination in older adults
por: Pawelec, Graham, et al.
Publicado: (2021)

Multicomponent vaccines to fight SARS-CoV-2 variants of concern
por: Cassone, Antonio, et al.
Publicado: (2021)

SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination?
por: Antonopoulou, Tania, et al.
Publicado: (2022)

Questioning the justification for a fourth SARS-CoV-2 vaccine
por: Calderon-Margalit, Ronit, et al.
Publicado: (2022)

Routine Antigen Testing Is Not a Substitute for Health Care Worker Vaccination against SARS-CoV-2
por: Sexton, Mary Elizabeth, et al.
Publicado: (2021)

Rapid and robust bioanalytical assays are critical for SARS-CoV-2 therapeutic and vaccine development and beyond
por: Kar, Sumit, et al.
Publicado: (2020)

No credible evidence supporting claims of the laboratory engineering of SARS-CoV-2
por: Liu, Shan-Lu, et al.
Publicado: (2020)

RNA interference as a promising treatment against SARS-CoV-2
por: Donia, Ahmed, et al.
Publicado: (2020)

SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines
por: Salvatori, Giovanni, et al.
Publicado: (2020)

Pregnant people deserve the protection offered by SARS-CoV-2 vaccines
por: Maykin, Melanie M., et al.
Publicado: (2021)

Positive aspects of the mRNA platform for SARS-CoV-2 vaccines
por: Hajissa, Khalid, et al.
Publicado: (2021)

COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants
por: Cevik, Muge, et al.
Publicado: (2021)

SARS-CoV-2 vaccination for immune-comprised patients: More is required
por: Li, Hui, et al.
Publicado: (2021)

Diagnosis of Acute Myocarditis Following mRNA Vaccines against SARS-CoV-2: A Methodological Review
por: Zuin, Marco, et al.
Publicado: (2023)

Ring vaccination of COVID‐19 vaccines in medium‐ and high‐risk areas of countries with low incidence of SARS‐CoV‐2 infection
por: Xu, Wei, et al.
Publicado: (2021)

Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks
por: Billington, John, et al.
Publicado: (2020)

Guangdong’s Study of the Effectiveness of China’s Inactivated Vaccines Against the SARS-CoV-2 B.1.617.2 (Delta) Variant
por: Wang, Fuzhen, et al.
Publicado: (2021)

Mechanism of action of favipiravir against SARS-CoV-2: Mutagenesis or chain termination?
por: Zhao, Lei, et al.
Publicado: (2021)

Extracellular vesicles: A promising therapy against SARS-CoV-2 infection
por: Leyfman, Yan, et al.
Publicado: (2023)

Skin rashes after SARS‐CoV‐2 vaccine: which relationship, if any?
por: Patruno, Cataldo, et al.
Publicado: (2021)

Increasing SARS-CoV-2 vaccination rates among Black people in Canada
por: Eissa, Azza, et al.
Publicado: (2021)

Pathogenicity of SARS‐CoV‐2 Omicron
por: Chu, Hin, et al.
Publicado: (2022)

Antigenic imprinting in SARS‐CoV‐2
por: Reincke, S. Momsen, et al.
Publicado: (2022)

Precautions after vaccinating immunosuppressed patients with mRNA-based vaccines against SARS-CoV-2: does one size fit all?
por: Tau, Noam, et al.
Publicado: (2021)

Development of an Inactivated Vaccine against SARS CoV-2
por: Pavel, Shaikh Terkis Islam, et al.
Publicado: (2021)

The development of DNA vaccines against SARS-CoV-2
por: Khalid, Kanwal, et al.
Publicado: (2023)

SARS-CoV-2 vaccination in the context of original antigenic sin
por: Petráš, Marek, et al.
Publicado: (2021)

The potential risks of delaying the second vaccine dose during the SARS-CoV-2 pandemic
por: Humphreys, I R, et al.
Publicado: (2021)

Why we may need to rethink future SARS-CoV-2 vaccination strategies
por: Klimek, Peter
Publicado: (2021)

Validation of the effectiveness of SARS-CoV-2 vaccines in older adults in “real-world” settings
por: Weng, Nan-ping, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_10sfouqc80ln9tupltlkfrlrf9